CD19 and diffuse large B-cell lymphoma: This is critical as our preclinical mouse data – demonstrating a more rapid cytotoxicity of CD19.CD28 CAR-T cells and a sustained persistence of CD19.4–1BB CAR-T cells – is in accord with clinical trial outcomes showing higher efficacy of the former in diffuse large B-cell lymphoma and prolonged persistence of the latter Maude et al. (2014), Maude et al. (2018), Cheng et al. (2018), Aamir et al. (2021).